Introduction/Aim. Epidermal growth factor receptor (EGFR) is one of the key tumor markers of non-small cell lung cancer (NSCLC) and a guideline for the choice of therapeutic procedures. The research aims to evaluate the methods used in the investigation of EGFR variants in NSCLC cell lines and combined research (NSCLC cell lines and patient samples) in the last decade in different geographical areas. Methods. The study included 185 full-text articles in which EGFR mutations were examined on NSCLC cell lines and 37 full-text articles analyzed EGFR variants on combined research, published from January 1, 2010, to April 2020. A descriptive statistic was done using a pivot table in Microsoft Excel 2007 original software. Results. The obtained results showed that Western blot, MTT Cell Viability Assay, and Polymerase Chain Reaction (PCR) were used the most in the evaluation of EGFR variants on NSCLC cell lines. In combined research of EGFR variants on cell lines and samples obtained from patients, sequencing, PCR, and Western blot are mostly used. The largest number of published articles of both groups research was published on the Asian continent. Conclusion. There is a difference in the frequency of the most commonly used methods in testing EGFR variants in research on NSCLC cell lines and in combined studies, and the common feature of both types of research is that most of the published full-text articles on EGFR gene variation in NSCLC originate from the Asian continent in the last decade.
References
1.
Greve G, Schiffmann I, Pfeifer D, Pantic M, Schüler J, Lübbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15(1).
2.
Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings. 2019;94(8):1623–40.
3.
Zhang Q, Li D, Liu Y, Wang H, Zhang C, Huang H, et al. Potential anticancer activity of curcumin analogs containing sulfone on human cancer cells. Archives of Biological Sciences. 2016;68(1):125–33.
4.
Turkez H, Arslan ME, Ozdemir O. Genotoxicity testing: progress and prospects for the next decade. Expert Opinion on Drug Metabolism & Toxicology. 2017;13(10):1089–98.
5.
Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-α on Raji cells at different cellular levels estimated by various methods. Annals of Hematology. 2006;85(2):86–94.
6.
Vuletic A, Konjevic G, Milanovic D, Ruzdijic S, Jurisic V. Antiproliferative Effect of 13-cis-Retinoic Acid is Associated with Granulocyte Differentiation and Decrease in Cyclin B1 and Bcl-2 Protein Levels in G0/G1 Arrested HL-60 Cells. Pathology & Oncology Research. 2010;16(3):393–401.
7.
Jurisic V, Srdic-Rajic T, Konjevic G, Bogdanovic G, Colic M. TNF-α Induced Apoptosis is Accompanied with Rapid CD30 and Slower CD45 Shedding from K-562 Cells. The Journal of Membrane Biology. 2011;239(3):115–22.
8.
Rice SJ, Liu X, Wang HG, Belani CP. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer. PLOS ONE. 14(5):e0217657.
9.
Maj E, Maj B, Bobak K, Gos M, Chodyński M, Kutner A, et al. Differential Response of Lung Cancer Cells, with Various Driver Mutations, to Plant Polyphenol Resveratrol and Vitamin D Active Metabolite PRI-2191. International Journal of Molecular Sciences. 22(5):2354.
10.
Radenkovic S, Konjevic G, Nikitovic M. Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients. J BUON. 2021;26(2):475–82.
11.
Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, et al. A gene-alteration profile of human lung cancer cell lines. Human Mutation. 2009;30(8):1199–206.
12.
Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW, et al. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Cells. 8(12):1538.
13.
Baidyuk E, Shuvalov O, Daks A, Fedorova OA, Vorobev M, Piacentini M, et al. Nucleolar localization of EGFR with different status in lung adenocarcinoma cells. Biopolymers and Cell. 2019;35(3):200–200.
14.
Todosijević J, Luković J, Obradović J, Jurišić V. BASIC RESEARCH OF LUNG CANCER IN-VITRO: MEASUREMENT METHODS, NEW POSSIBILITIES AND PERSPECTIVE. RAP Conference Proceedings.
15.
Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1(1):5–13.
16.
Cheng CC, Chou KF, Wu CW, Su NW, Peng CL, Su YW, et al. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer. Lung Cancer. 2018;116:80–9.
17.
Herreros-Pomares A, Zhou X, Calabuig-Fariñas S, Lee SJ, Torres S, Esworthy T, et al. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study. Materials Science and Engineering: C. 2021;122:111914.
18.
Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications. 10(1).
19.
Shi R, Radulovich N, Ng C, Liu N, Notsuda H, Cabanero M, et al. Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer. Clinical Cancer Research. 2020;26(5):1162–74.
20.
Naoki K, Soejima K, Okamoto H, Hamamoto J, Hida N, Nakachi I, et al. The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International Journal of Clinical Oncology. 2011;16(4):335–44.
21.
Forcella M, Oldani M, Epistolio S, Freguia S, Monti E, Fusi P, et al. Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3. PLOS ONE. 12(10):e0187289.
22.
Jiang X, Liu W, Zhu X, Xu X. Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays. Molecular Medicine Reports.
23.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.
24.
Lam DCL, Liam CK, Andarini S, Park S, Tan DSW, Singh N, et al. Lung Cancer Screening in Asia: An Expert Consensus Report. Journal of Thoracic Oncology. 2023;18(10):1303–22.
25.
Nowacka M, Sterzynska K, Andrzejewska M, Nowicki M, Januchowski R. Drug resistance evaluation in novel 3D in vitro model. Biomedicine & Pharmacotherapy. 2021;138:111536.
26.
Obradović J, Djordjević N, Tošic N, Mrdjanović J, Stanković B, Stanić J, et al. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumor Biology. 2016;37(8):10479–86.
27.
Lichota A, Gwozdzinski K. Anticancer Activity of Natural Compounds from Plant and Marine Environment. International Journal of Molecular Sciences. 19(11):3533.
28.
Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjević N. EGFRPolymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. Journal of Oncology. 2020;2020:1–14.
29.
Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Research. 2012;22(12):2315–27.
30.
Alberg AJ, Samet JM. Epidemiology of Lung Cancer*. Chest. 2003;123(1):21S-49S.
31.
HUBBARD R, VENN A, LEWIS S, BRITTON J. Lung Cancer and Cryptogenic Fibrosing Alveolitis. American Journal of Respiratory and Critical Care Medicine. 2000;161(1):5–8.
32.
Kirk GD, Merlo C, O’Driscoll P, Mehta SH, Galai N, Vlahov D, et al. HIV Infection Is Associated with an Increased Risk for Lung Cancer, Independent of Smoking. Clinical Infectious Diseases. 2007;45(1):103–10.
33.
Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 2022;17(3):362–87.
34.
Chen P, Liu Y, Wen Y, Zhou C. Non‐small cell lung cancer in China. Cancer Communications. 2022;42(10):937–70.
35.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology. 2015;10(9):1243–60.
36.
Yatabe Y. Molecular pathology of non‐small cell carcinoma. Histopathology. 2024;84(1):50–66.
37.
Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958–70.
38.
Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. European Journal of Cancer. 2001;37:9–15.
39.
Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer and Metastasis Reviews. 2016;35(4):575–88.
40.
Verusingam ND, Chen YC, Lin HF, Liu CY, Lee MC, Lu KH, et al. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. Journal of the Chinese Medical Association. 2021;84(3):248–54.
41.
Provenzano M, Mocellin S. Complementary Techniques. Advances in Experimental Medicine and Biology. p. 66–73.
42.
Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, et al. Identification and Validation of Differences in Protein Levels in Normal, Premalignant, and Malignant Lung Cells and Tissues Using High-Throughput Western Array and Immunohistochemistry. Cancer Research. 2006;66(23):11194–206.
43.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021;71(1):7–33.
44.
OKADA S, KOBAYASHI S, INABA H, SATO N, HASUMI T, SHOJI W, et al. Flow Cytometric DNA Analysis of Lung Cancer Cell Lines. The Tohoku Journal of Experimental Medicine. 1992;168(2):307–10.
45.
Neuperger P, Puskás GL, Szebeni JG. A humán H1975 tüdőés MDA-MB-231 emlőadenokarcinóma-sejtes modellek egysejttömegcitometriás összehasonlító elemzése [Single cell mass cytometric comparison of human H1975 lung and MDA-MD-231 breast adenocarcinoma cellular models. Magy Onkol. 2021;65(2):129–38.
46.
Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, et al. Long-read sequencing for non-small-cell lung cancer genomes. Genome Research. 2020;30(9):1243–57.
47.
Mirabelli P, Coppola L, Salvatore M. Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers. 11(8):1098.
48.
Hynds RE, Frese KK, Pearce DR, Grönroos E, Dive C, Swanton C. Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology. 2021;11(1).
49.
Tsai JR, Wang HM, Liu PL, Chen YH, Yang MC, Chou SH, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cellular Oncology. 2012;35(6):461–71.
50.
Guernet A, Mungamuri SK, Cartier D, Sachidanandam R, Jayaprakash A, Adriouch S, et al. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Molecular Cell. 2016;63(3):526–38.
51.
Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, et al. Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine. 2011;183(8):1071–9.
52.
Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Molecular Biology Reports. 2021;48(4):3593–604.
53.
Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer. 2014;14(8):535–46.
54.
Yablonskii P, Nefedov A, Arseniev A, Kozak A, Mortada M, Patsyuk A. Non-small cell lung cancer, pleural effusion and carcinomatosis: always a criterion of inoperability? AME Medical Journal. 5:10–10.
55.
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer. 2017;17(11):637–58.
56.
Padinharayil H, Varghese J, John MC, Rajanikant GK, Wilson CM, Al-Yozbaki M, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes & Diseases. 2023;10(3):960–89.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
